Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IMpower131

- PMLiVE

Hardy returns to Genentech as CEO

In other news, Vertex fires chief operating officer

- PMLiVE

Neoantigen player Achilles gets OK for first clinical trial

Will test the candidate in advanced NSCLC patients

- PMLiVE

Nektar confirms BMS deal for NKTR-214 is on track

Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference

- PMLiVE

Chugai gains FDA breakthrough status for rare CNS treatment

Adds to company's BTD roll-call

- PMLiVE

Roche gains EU PRIME status for Spinraza rival

Oral treatment joins Novartis' gene therapy challenger

- PMLiVE

AZ still sees route to approval for Imfinzi in MYSTIC trial

New analysis shows opportunity in NSCLC

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

Roche Basel Switzerland

Roche builds on Immunocore ImmTAC deal

Extends partnership to target MAGE-A4 protein tumours

- PMLiVE

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Another setback for Roche, but CHMP changes its mind on Opdivo/Yervoy

- PMLiVE

AZ’s MYSTIC survival data is in – and it’s a bust

Imfinzi failed to achieve OS improvement

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

- PMLiVE

Pfizer claims rapid FDA nod for Lorbrena

Green light is latest in a string of cancer drug approvals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links